Connacher A A, Bennet W M, Jung R T
Department of Medicine, Ninewells Hospital and Medical School, Dundee, Scotland, UK.
Am J Clin Nutr. 1992 Jan;55(1 Suppl):258S-261S. doi: 10.1093/ajcn/55.1.258s.
BRL 26830A is a beta-adrenoceptor agonist drug that shows a high degree of selectivity for thermogenesis and has potential as an antiobesity agent. We undertook a double-blind trial in 40 obese subjects who received either BRL 26830A or placebo for 18 wk. All were prescribed a 3.35 MJ (800 kcal) diet. Weight loss was 15.4 +/- 6.6 (SD) kg on BRL 26830A compared with 10.0 +/- 5.9 kg on placebo (P less than 0.02). The relative weight losses were 0.93% and 0.61%/wk, respectively. Urinary nitrogen excretion was similar in both groups and skinfold measurements indicated a 4-kg difference in fat lost, suggesting that weight loss was mainly from adipose tissue. Psychological assessments showed that BRL 26830A had no adverse effect on mood and no effect on hunger or satiety. Tremor was experienced by 12 of 16 treated subjects who completed the study. It was generally rated as mild, occurred 1 h after dosing, and tended to diminish with time on treatment. Subsequent analysis of the tremor suggested that it is an exaggeration of physiological tremor mediated through skeletal muscle beta 2 adrenoceptors.
BRL 26830A是一种β-肾上腺素能受体激动剂药物，对产热表现出高度选择性，具有作为抗肥胖药物的潜力。我们对40名肥胖受试者进行了一项双盲试验，这些受试者接受BRL 26830A或安慰剂治疗18周。所有受试者都被规定摄入3.35兆焦耳（800千卡）的饮食。接受BRL 26830A治疗的受试者体重减轻了15.4±6.6（标准差）千克，而接受安慰剂治疗的受试者体重减轻了10.0±5.9千克（P<0.02）。相对体重减轻分别为每周0.93%和0.61%。两组的尿氮排泄相似，皮褶测量表明脂肪减少量相差4千克，这表明体重减轻主要来自脂肪组织。心理评估显示，BRL 26830A对情绪没有不良影响，对饥饿或饱腹感也没有影响。完成研究的16名接受治疗的受试者中有12人出现了震颤。震颤一般被评为轻度，在给药后1小时出现，并且随着治疗时间的推移有减轻的趋势。对震颤的后续分析表明，它是由骨骼肌β2肾上腺素能受体介导的生理性震颤的增强。
